Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

Have you been paying attention to shares of Cencora (COR) ? Shares have been on the move with the stock up 9.1% over the past month. The stock hit a new 52-week high of $239.86 in the previous session. Cencora has gained 16.1% since the start of the year compared to the 7.8% move for the Zacks Medical sector and the 5.7% return for the Zacks Medical Services industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensu ...

The Medical Services sector is evolving at a rapid pace. The COVID-19 pandemic accelerated the transition to remote treatment options. Even though the pandemic has ended, digital healthcare treatment continues to be indispensable, backed by the adoption of data and analytics. Telemedicine-focused online medical and AI-powered technology services, which flourished during the pandemic, continue to witness significant demand.Going by a recent WNS report, the global healthcare analytics market is expected to su ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended. Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent shar ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) common stock pursuant to Rule 144 for proceeds of approximately $942 million and, subject to the completion of the Rule 144 sale, a concurrent share repurchase by Cencora in the amount of approximately $50 million. Walgreens Boots Alliance’s ownership of Cencora’s common stock has decreased from approximately 15 percent to approximately 13 percent. Proceeds to ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 23, 2021. Cencora intends to use the net proceeds from the offering to redeem all of its 3.400% Sen ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritten registered public offering. The offering is being made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 23, 2021. The offering is expected to close on February 7, 2024, subject to the satisfaction of customary closing cond ...

For the quarter ended December 2023, Cencora (COR) reported revenue of $72.25 billion, up 15% over the same period last year. EPS came in at $3.28, compared to $2.71 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $68.81 billion, representing a surprise of +5.00%. The company delivered an EPS surprise of +14.69%, with the consensus EPS estimate being $2.86.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

First quarter highlights & strategic overview Financial results 22.0% U.S. Healthcare Solutions segment operating income growth y/y Effective tax rate 23.0% 21.0% Cencora, Inc. First Quarter Fiscal 2024 Earnings Call January 31, 2024 In an effort to provide additional and useful information regarding Cencora's financial results and other financial information as determined by generally accepted accounting principles (GAAP), certain materials presented during this event include non-GAAP information. A reconc ...

Cencora, Inc. (NYSE:COR) Q1 2024 Earnings Conference Call January 31, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head IR & Treasury Steve Collis - Chairman, President & CEO Jim Cleary - EVP & CFO Conference Call Participants Stephanie Davis - Barclays Lisa Gill - JPMorgan Eric Percher - Nephron Research Daniel Grosslight - Citibank Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of America Erin Wright - Morgan Stanley Charles Rhyee - TD Cowen Eric Coldwell - Baird George Hill - Deutsche ...